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Abstract
Focal adhesion kinase (FAK) plays an important role in signal transduction pathways initiated at sites of integrin-mediated
cell adhesion to the extracellular matrix. Thus, FAK is involved in many aspects of the metastatic process including adhesion,
migration and invasion. Recently, several small molecule inhibitors which target FAK catalytic activity have been developed
by pharmaceutical companies. The current study was aimed at addressing whether inhibiting FAK targeting to focal
adhesions (FA) represents an efficient alternative strategy to inhibit FAK downstream pathways. Using a mutagenesis
approach to alter the targeting domain of FAK, we constructed a FAK mutant that fails to bind paxillin. Inhibiting FAK-
paxillin interactions led to a complete loss of FAK localization at FAs together with reduced phosphorylation of FAK and FAK
targets such as paxillin and p130Cas. This in turn resulted in altered FA dynamics and inhibition of cell adhesion, migration
and invasion. Moreover, the migration properties of cells expressing the FAK mutant were reduced as compared to FAK-/-
cells. This was correlated with a decrease in both phospho-Src and phospho-p130Cas levels at FAs. We conclude that
targeting FAK-paxillin interactions is an efficient strategy to reduce FAK signalling and thus may represent a target for the
development of new FAK inhibitors.
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Introduction
In many cancers, progression of the disease results predomi-
nantly from the formation of metastases. FAK is involved in many
aspects of the metastatic process including adhesion, migration,
secretion of MMPs (matrix metalloproteinases) and invasion.
Indeed, numerous reports have described overexpression, hyper-
phosphorylation and/or elevated activity of FAK in a variety of
human cancers, including sarcomas, astrocytomas and carcinomas
of the breast, colon, thyroid, prostate, oral cavity, liver, stomach
and ovary [1]. These observations highlight a possible key role of
FAK in tumourigenesis. The first experimental proof implicating
FAK in tumour formation and progression was obtained by using
conditional knock-out mice with selective fak deletion in the
epidermis [2]. This proof of concept experiment served as the
cornerstone for the development of strategies aimed at inhibiting
FAK activity using small-interfering RNAs [3] or small molecule
inhibitors. For the latter class, almost all compounds, including PF-
562,271 [4], PF-573,228 [5] or TAE226 [6], developed by
pharmaceutical companies are ATP-competitive tyrosine kinase
inhibitors of FAK. Nevertheless, as FAK possesses both catalytic
and scaffolding functions, an alternative possibility to inhibit FAK
signalling is to block the adaptor function of FAK. This has been
successfully achieved using a small molecule that targets the
binding site of FAK and VEGFR3, resulting in suppressed breast
cancer growth in vivo in mouse models [7].
FAK is a ubiquitously expressed nonreceptor cytoplasmic
tyrosine kinase composed of an N-terminal FERM (band 4.1,
ezrin, radixin, moesin homology) domain, a central kinase
domain, several proline-rich domains and a C-terminal focal
adhesion targeting (FAT) domain. The C-terminal domain
interacts with focal adhesion (FA)-associated proteins including
paxillin and talin [8,9], p130Cas [10], Grb2 [9], ASAP1 [11] and
p85a of PI3K [12]. Furthermore, the C-terminal domain is both
necessary and sufficient for localization of FAK to FAs. Structural
studies have revealed that FAK targeting to FAs is mediated via
FAK-paxillin interactions and to a lesser extent, via FAK-talin
interactions. The FAT (Focal Adhesion Targeting) domain of FAK
is a four helix bundle containing a large hydrophobic core
stabilized by paxillin binding [13,14]. The 2 paxillin-binding sites
present in the FAT domain consist of surface exposed hydropho-
bic patches (HP). HP1 is located at the surface of helix 2–3
whereas HP2 is located at the surface of helix 1–4. Early
experiments using replacement of the FAT sequence of FAK
demonstrated that recruitment of FAK to FAs is essential for its
regulation by integrin signalling [15]. Moreover, experiments
using FRNK (Focal adhesion kinase-Related Non Kinase), the
dominant negative form of FAK, which displaces FAK from
adhesion sites indicate that many aspects of FAK function require
FAK targeting to FAs. Indeed, when overexpressed in cells, FRNK
acts as a negative regulator of FAK activity, inhibiting phosphor-
ylation of FAK and various FAK-related processes, including cell
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cycle progression [16,17], cell spreading on fibronectin and
migration [18,19]. Overexpression of FRNK in v-Src-transformed
NIH3T3 fibroblasts inhibited cell invasion and blocked experi-
mental metastases in nude mice [20]. These data are consistent
with displacement of FAK from FAs having a crucial role in FAK
signalling-mediated invasion-related processes such as adhesion,
migration, invadopodia formation and MMP secretion.
The aim of the present study was to assess the effects resulting
from inhibition of FAK-paxillin interactions. Using a mutated
form of FAK that does not bind paxillin, we show for the first time
that this mutant causes reduction of adhesion, migration and
invasion, to a greater extent than that observed in FAK-/- cells
demonstrating gain of function effects. Our findings demonstrate
that targeting specific FAK-paxillin interactions may be of
potential therapeutic interest. Development of such site-specific
inhibitors might represent a promising strategy to prevent tumour
metastasis.
Materials and Methods
Reagents and antibodies
Dulbecco’s modified Eagle’s medium (DMEM), AlexaFluor
555-conjugated goat anti-mouse IgG and Lipofectamine 2000
were from Invitrogen. Fetal bovine serum (FBS), penicillin,
streptomycin and trypsin-EDTA solutions were from Lonza.
ReBlot Plus stripping reagent and monoclonal anti-cortactin anti-
body (Ab) (clone 4F11) were from Millipore. Human fibronectin,
mouse monoclonal anti-FAK kinase, mouse monoclonal anti-
phospho-paxillin (Y118) and mouse monoclonal anti-p130Cas Abs
were from BD Biosciences. Rabbit anti-phospho-Y925 FAK Ab
was from US Biological. Mouse monoclonal anti-paxillin, rabbit
polyclonal anti-phospho-Y397 FAK, rabbit anti-phospho-Y576
FAK and rabbit anti-phospho-Y861 FAK Abs were from
Invitrogen. Mouse monoclonal anti-b-actin and talin Abs were
from Sigma. Mouse monoclonal anti-Src, rabbit polyclonal anti-
phospho-p130Cas (Y410) and anti-Y416-phospho-Src Abs were
from Cell Signaling. Horseradish peroxidase-conjugated goat anti-
mouse or anti-rabbit IgG were from Promega. Rhodamine Red
X-conjugated goat anti-mouse, rhodamine Red X-conjugated
mouse anti-rabbit, and CY5-conjugated donkey anti-mouse Abs
were from Jackson ImmunoResearch Labs.
Expression vectors
pAcGFP1-Hyg-C1-FAK (human wild-type FAK fused to Cter
of GFP) was constructed by inserting the FAK PCR amplified
insert in the BglII/SalI restriction sites of pAcGFP1-Hyg-C1
(Clontech). The I936E-I998E-FAK (FAKI936/I998) double mutant
was generated using the QuikChange II XL site-directed mutagen-
esis kit (Agilent Technologies). Briefly, pAcGFP1-Hyg-C1-FAK was
used as a template to generate the FAKI936/I998construct using
FAKI936E-S (59-GCCTGGTGAAAGCTGTCGAGGAGATG-
TCCAGTAAAATCCAGC-39), FAKI936E-AS (59-GCTGGAT-
TTTACTGGACATCTCCTCGACAGCTTTCACCAGGC-39),
FAKI998E-S (59-GAACTCTGACCTGGGTGAGCTCGAAAA-
CAAGATGAAACTGGCC-39), and FAKI998E-AS (59-GGCCA-
GTTTCATCTTGTTTTCGAGCTCACCCAGGTCAGAGTTC
-39) primers. pcDNA3.1-mCherry-SrcY530F was generated by
inserting the PCR product mCherry-SrcY530F in pcDNA3.1(zeo)
(Invitrogen). All constructs were amplified and purified using
Qiagen Hispeed Maxiprep kits and specific point mutations were
verified by sequencing.
Cell line, transfection and fibronectin stimulation
Primary FAK-/- mouse embryonic fibroblasts (MEFs) [21] were
maintained in DMEM supplemented with 10% FBS, 100 U/ml
penicillin and 100 mg/ml streptomycin as previously described
[22]. Transfection of primary FAK-/- cells with wild type or
mutant FAK fused to GFP were performed using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s directions. To
generate stable populations, 48 h after transfection 150 mg/ml
hygromycin was added to allow selection of the transfected cells.
After 1 week of hygromycin selection, cells were sorted by FACS.
For cells expressing mCherry-SrcY530F, FAK-/- and WT or mutant
GFP-FAK cells were transfected using Lipofectamine 2000,
selected by zeocin for 10 days, and sorted by FACS. For
fibronectin stimulation, cells were serum-starved for 24 h, and
then seeded onto 10 mg/ml fibronectin precoated culture dishes.
Cell lysis, immunoprecipitation, and immunoblotting
30 min after stimulation on fibronectin, cells were rinsed 2x
with ice-cold PBS (pH 7.4) and lysed with ice-cold IP lysis buffer
(137 mM NaCl, 1% Nonidet P-40, 20 mM Tris-HCl, pH 8.0,
glycerol 10%, 3 mM Na3VO4, protease inhibitor tablet [Complete
mini, Roche]). Lysates were cleared by centrifugation and protein
concentrations determined. For immunoprecipitation, cells were
first co-transfected with either FAK-GFP or FAKI936/I998-GFP
and CFP-paxillin or GFP-talin using Lipofectamine 2000. 500 mg
of cell lysates were then incubated with specific Abs (at dilutions
recommended by manufacturers) for 3 h at 4uC with continuous
shaking. Protein G sepharose beads (Amersham) were then added
for overnight incubation. Beads were collected, washed 3x with
ice-cold IP buffer and then resuspended in Laemmli buffer. For
Western blots, cells were rinsed 2x with ice-cold PBS (pH 7.4) and
lysed for 30 min on ice with RIPA buffer. 20 mg of protein lysates
were resolved by SDS-10% PAGE and transferred to PVDF
membranes (Hybond-P, GE Healthcare). Blocking of membranes
was done in 5% nonfat milk-TBST (10 mM Tris-HCl, pH 7.4,
150 mM NaCl, 0.1% Tween 20) for 1 h at room temperature
before overnight incubation at 4uC with primary Abs (diluted 1/
1000 in 5% nonfat milk-TBST). After 3 washes with TBST,
membranes were incubated with corresponding horseradish
peroxidase-conjugated secondary Abs (1/20000). Signals were
assessed using enhanced chemiluminescence (ECL Plus, GE
Healthcare) and CL-XPosure films (Fisher Scientific).
Adhesion, migration and invasion assays
For adhesion assays, 2.56104 cells were seeded in fibronectin-
coated 96-well plates, allowed to adhere for 1 h before being
washed in PBS/0.1% BSA. Cells were then fixed with 4%
paraformaldehyde for 10 min, washed and stained with crystal
violet (5 mg/ml in 2% ethanol) for 10 min at room temperature.
After 5 washes with H2O, the dye was extracted from the cells with
0.2% Triton X-100 and optical densities (ODs) measured at
595 nm. Percentages of adhesion were normalized to control cells.
For migration assays, cells were seeded on fibronectin-coated
IBIDI m-dishes until confluent. Cell layers were then scratched
with pipette tips and cells were allowed to migrate for 8 h. Images
of cells were taken at t = 0 and t = 8 h and analysed as previously
reported [23].
For migration and invasion assays using mCherry-SrcY530F
expressing cells, cells were seeded in migration or matrigel-coated
invasion chambers (BD Biosciences) and processed according to
the manufacturer’s protocol. Migrating or invading cells were
fixed with 4% PFA, stained with crystal violet and ODs measured
at 595 nm.
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Immunofluorescence microscopy
MEFs were plated at low density on 10 mg/ml fibronectin-
coated imaging m-dishes. After 24 h incubation, cells were fixed
with 4% PFA for 10 min, permeabilized in 0.1% Triton X-100 for
5 min, blocked in 1% BSA/PBS for 1 h and incubated with
primary Abs diluted at 1/100 to 1/300 in 1% BSA/PBS for 1 h at
room temperature. After 3 washes with PBS, cells were incubated
with rhodamine-conjugated donkey anti-mouse Ab (1/400), Alexa
555-conjugated goat anti-mouse Ab (1/250) or CY 5 conjugated
donkey anti-rabbit Ab (1/250) for 1 h, washed 3 times with PBS
and then observed using either a Bio-Rad 1024 confocal system
coupled to Nikon Eclipse TE300 microscope (606CFI Pl Fluor
1.3 NA objective) or a Leica confocal microscope TSC SPE (63x
HCX Pl Apo 1.40 NA objective) or a Leica DMIRE2 microscope
(40x HCX Pl Apo 1.25 NA and 63x HCX Pl Apo 1.32 NA
objectives). For dual wide-field-TIRF experiments cells were
imaged using an iMIC microscope (Till Photonics) equipped with
a Cobolt Dual Calypso Laser 491/532 nm, a monochromator
Polychrome V and an Olympus 60x TIRFM (1.45 NA) objective.
Automated counting of FAs in single cells was done after noise
removal by thresholding and applying a size constraint to FAs
using ImageJ software. To analyse the percentage of cells
expressing ventral adhesions, TIRF images were used and cells
with less than 5% of ventral adhesions were counted as negative.
For cortactin staining, cells were trypsinized 48 h after transfection
and replated on 10 mg/ml fibronectin-coated glass coverslips for
3 h. Cells were then fixed with 4% PFA in PBS for 20 min,
permeabilized in 0.5% Triton X-100 for 30 min, blocked in
0.05% BSA in PBS for 30 min and incubated with monoclonal
anti-cortactin Ab diluted (1/250) in PBS-BSA for 1 h at 37uC.
After 3 washes, cells were incubated with CY5-conjugated donkey
anti-mouse Ab (1/350) for 1 h at 37uC, washed 3 times with PBS
and mounted in Prolong Gold mounting media (Invitrogen).
TIRF experiments
For live cell imaging, confluent cells plated on fibronectin-
coated coverslips were scratched with a pipette tip prior to
imaging. TIRF (total internal reflection fluorescence) images were
then acquired using an iMIC microscope (Till Photonics) equipped
with a Topica iBeam laser (442 nm) and an Olympus 60x TIRFM
(1.45 NA) objective. During acquisition, cells were maintained at
37uC in a 5% CO2 humidified atmosphere using an environmen-
Figure 1. Analysis of FAK-paxillin interaction in wild-type FAK and FAKI936/I998 cells. (A) Structural view of the 4 helix bundle (a1-a4) of the
FAT domain. Paxillin binds to 2 hydrophobic patches located at the interface of a-helix 1/4 and the interface of a-helix 2/3. The I936E and I998E
mutations are indicated. (B) Representative blots showing wild-type FAK and FAKI936/I998 immunoprecipitated using anti-FAK Ab and blotted for
paxillin and FAK. The expression level of proteins in the corresponding cell lysate is shown. (C) Confocal images from fixed cells expressing wild-type
or mutant FAK (fused to GFP) and immunostained for a marker of FAs, paxillin (red). Note the absence of FAK at FAs in mutant cells. Scale bar, 20 mm.
doi:10.1371/journal.pone.0092059.g001
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tal control system (Life Imaging Services). TIRF images were
acquired every 1 min on an EMCCD camera (Andor Technology)
for 1 h and analysed using ImageJ software.
Statistical analysis
Data were analysed using either Student’s t-test or one way
ANOVA followed by post-hoc Newman-Keuls for multiple
comparisons. Two ways ANOVA followed by Bonferroni post-
tests were used to analyse the size distribution of FAs in the three
cell lines. Differences were considered to be significant at p#0.05.
Unless otherwise stated, all data presented are from at least 3
independent experiments.
Results
Expression of mutated FAK in the FAT domain alters FAK
localization and interaction with paxillin
In order to investigate how disruption of FAK-paxillin
interactions affects FAK phosphorylation and downstream signal-
ling pathways, site-directed mutagenesis was utilized to replace
Ile936 and Ile998 with glutamic acids Glu936 and Glu998 in the FAT
domain of FAK. These point mutations, for which both HP1 and
HP2 are mutated (Figure 1A), have been shown in vitro to
completely abrogate binding of truncated paxillin to the FAT
domain of FAK [13]. After confirmation of mutations by
sequencing, FAK-/- MEFs were transfected with wild-type FAK
Figure 2. Phosphorylation status of FAK and FAK substrates in FAK-/- cells re-expressing wild-type FAK and FAKI936/I998. (A) Graphs
show decreased FAK phosphorylation at Tyr397, Tyr576 and Tyr925 in FAKI936/I998 cells compared to wild-type FAK cells (*p,0.013, **p,0.0002; n = 4 to
6 independent experiments). (B) RepresentativeWestern blots showing the phosphorylation states of paxillin and p130Cas in FAK-/-, FAK and FAKI936/I998-
expressing cells. Graphs show decreased phosphorylation of paxillin in both FAKI936/I998 cells and FAK-/- cells (*p,0.03) compared to wild-type FAK cells
(P = 0.0097, F = 6.165) and decrease phosphorylation of p130CAS in FAKI936/I998 cells (***p,0.001) and FAK-/- cells (*p,0.05) compared to wild-type FAK
cells (p= 0.0004, F = 12.68; n = 3 to 8 independent experiments).
doi:10.1371/journal.pone.0092059.g002
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or FAKI936/I998 tagged with GFP. Both proteins were correctly
expressed at their expected molecular weights. Co-immunopre-
cipitation experiments were done to verify that these mutations
disrupt FAK interaction with paxillin. As shown in Figure 1B,
mutant FAKI936/I998 was almost completely unable to precipitate
paxillin contrarily to wild-type FAK, thus confirming the
requirement of intact HP sites in the FAT domain for FAK-
paxillin binding. In order to visualize how these mutations alter
FAK localization at FAs, immunofluorescence labelling of MEFs
expressing wild-type FAK or FAKI936/I998 was done. While FAs
were clearly identified in both cell lines by paxillin staining, the
FAK mutant is localized into the cytoplasm and not at FAs as
shown by the absence of merged signals of FAK with paxillin
(Figure 1C). On the other hand, as talin interacts with both FAK
and FAKI936/I998 and appears correctly localized at FAs in both
cell lines (Figure S1), talin may not be an alternative route to
localize FAK at FAs thus confirming recent studies [24].
Figure 3. Quantification of focal adhesions in FAK, FAKI936/I998 and FAK-/- cells. (A) Confocal images from fixed FAK-/- cells expressing or not
wild-type or mutant FAK-GFP and immunostained for paxillin. Evaluation of paxillin-containing FAs reveals no significant decrease in the number of
FAs in FAKI936/I998 cells as compared to FAK-/- and FAK cells (P = 0.0602, F = 2.958; n = 3 independent experiments with 15 to 28 cells and more than
600 FAs counted per condition). Scale bar, 20 mm. (B) Size-distribution of FAs shows a clear deficit of sub-micron sized FAs in FAKI936/I998
(0,FA,0.5 mm2 ***p,0.001; 0.5,FA,1 mm2 **p,0.01) and FAK-/- cells (0,FA,0.5 mm2 ***p,0.001) compared to FAK cells.
doi:10.1371/journal.pone.0092059.g003
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Expression of FAKI936/I998 alters the phosphorylation
states of FAK and FAK downstream substrates
To analyse the effects of the FAKI936/I998 mutation on the state
of phosphorylation at tyrosine sites, Western blots were done using
phosphospecific Abs that recognize phosphorylation at Tyr397,
Tyr576, Tyr861 and Tyr925 of FAK. Phosphorylation at Tyr861 was
only slightly affected by mutations of FAK in the FAT domain
whereas phosphorylation at Tyr397, Tyr576 and Tyr925 was
significantly decreased by 72%, 89% and 72% respectively
(Figure 2A). FAK kinase activity also regulates downstream
Figure 4. Effects of FAKI936/I998 expression on FA dynamics. (A) Representative TIRF images of FAK, FAKI936/I998 and FAK-/- cells. Formation of
nascent adhesions at the front and dissociation of FAs at the rear (arrows) in FAK, FAKI936/I998 and FAK-/- cells transfected with CFP-paxillin. Arrows
point to disassembling FAs at the trailing edge. Insets are magnified views of nascent adhesions over time in the yellow ellipses. Images were
acquired at 1 min intervals for 1 h (scale bar, 5 mm) and representative images from the time-lapse sequence are shown at 2 min intervals. Colour
images represent the superposition of images taken at t0 (red) and t60 (green). (B) Percentages of stable FAs were calculated from images in (A) as the
number of FAs in FAK, FAKI936/I998 and FAK-/- cells at t = 60 min compared to t = 0. (P = 0.0055, F = 9.145; *p,0.03, n = 3 independent experiments).
doi:10.1371/journal.pone.0092059.g004
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substrates including paxillin and p130Cas. In order to characterize
the effect of inappropriate FAK location on activation of paxillin
and p130Cas, Western blot analysis using Abs against paxillin and
p130Cas was done. The results show that FAK mutated at I936/
I998 significantly reduced paxillin phosphorylation by 29%
compared to wild-type FAK which is comparable to the 32%
reduction observed in FAK-/- cells (Figure 2B). On the other hand,
p130Cas phosphorylation was reduced by 38% in FAKI936/I998
cells as compared to wild-type FAK cells, which is slightly higher
than the 28% decrease observed in FAK-/- cells (Figure 2B). This
indicates first that FAK-paxillin interaction is crucial for maximal
phosphorylation of these substrates of FAK. Moreover, the
decrease in p130Cas phosphorylation may be accounted for the
lack of FAK localization at FAs, based on our previous
observations showing that p130Cas is mainly phosphorylated in
FAs of fibroblasts.
Altered FAK-paxillin interactions affect focal adhesion
dynamics
We and others have demonstrated that FAK phosphorylation is
essential for the regulation of FA turn-over [25,26]. Numerous
studies have also confirmed the implication of paxillin phosphor-
ylation in this process. As FAK mutated at I936 and I998
decreases both FAK and paxillin phosphorylation, we investigated
whether this could lead to impaired FA dynamics. For this
purpose, we evaluated the number and size of FAs in FAK-/-
MEFs and MEFs expressing wild-type FAK or FAKI936/I998. Cells
were seeded on fibronectin-coated coverslips and processed for
paxillin immunolabeling (Figure 3A), as paxillin has been shown to
be a reliable marker of FAs [27]. We first observed that cells
expressing FAKI936/I998 display a small, non significant reduction
of the number of FAs (4164) as compared to FAK cells (5665)
and FAK-/- cells (6066) (Figure 3B). Further analysis of the size
distribution of FAs revealed a drastic decrease in submicron-sized
FAs, which suggests an impaired mechanism for nascent FA
formation and/or an alteration in the FA disassembly process. A
similar phenotype, present to a lesser extent, was also observed in
FAK-/- cells, with the distribution of FAs being shifted to sizes
.1 mm2 (Figure 3B). To gain insight into these processes, FAK-/-
MEFs and FAK-/- MEFs expressing wild-type FAK or FAKI936/I998
were co-transfected with CFP-paxillin, grown to confluence,
wounded by scraping with a pipette tip, and tracked over 1 h using
live cell TIRF microscopy. Time lapse acquisition in TIRF mode of
images of FAK-/- cells (Movie S1), FAK cells (Movie S2) and
FAKI936/I998 (Movie S3) cells showed newly formed nascent FAs at
protruding leading edges and disassembly FAs at trailing edges
(Figure 4A). It is noteworthy that both FA formation at the cell front
and FA disassembly at the cell rear were impaired in FAKI936/I998
cells compared to FAK cells. Quantification of FA dynamics shows
that 35% of FAs remained stable during the observation period in
wild-type FAK cells whereas this percentage increased to 47% in
FAK-/- cells and to 58% in FAKI936/I998 cells (Figure 4B). These
data confirm that FAK-paxillin interaction plays a critical role in
regulating FA turnover.
Altered FAK-paxillin interactions disrupt cell adhesion
and migration
We next investigated whether FAKI936/I998 impaired cell
adhesion and migration. Adhesion assays revealed that MEFs
expressing FAKI936/I998 were less efficient in adhering on
fibronectin-coated dishes compared to MEFs expressing wild-type
FAK and FAK-/- cells (Figure 5A). Next, wound healing
experiments were done to evaluate how the lack of FAK
localization at FAs affects cell migration (Figure 5B). To this
end, FAK-/-, wild-type FAK and FAKI936/I998 cells were grown to
confluence, wounded by scraping with a pipette tip, and images of
wounded areas were taken at t = 0 and after 8 h of migration.
Distances of migration during this time were then determined for
each cell line and showed that wild-type FAK cells (26866 mm)
migrated significantly further than FAK-/- cells (24368 mm) and
FAKI936/I998 cells (164617 mm). Thus, expression of FAKI936/I998
decreased migration speed by 30% compared to control FAK-/-
cells and by 40% compared to wild-type FAK cells (Figure 5B).
Taken together, given that FAKI936/I998 cells display significantly
reduced adhesion and migration compared to FAK-/- cells, this
suggests an alteration in the pathways involved in invasion
processes that could be linked to the displacement of key partners
out of FAs.
Decreased cell invasion of FAKI936/I998 cells
It is well known that permanently active kinases like vSrc or
SrcY530F have transforming capabilities leading to aberrant cell
morphology in culture. This is especially well described in Src-
transformed mouse fibroblasts where Src induced the formation of
specialized structures dedicated to invasion processes. We there-
fore utilized this property to evaluate the effect of FAK mutation
on cell invasion. Thus, FAK-/- MEFs and MEFs expressing wild-
type FAK or FAKI936/I998 were transfected with mCherry-
SrcY530F. Src-induced transformation of FAK cells resulted in
the appearance of invasive structures at the cortex that were
characterized by cortactin enrichment, visible as clusters
(Figure 6A top panels, arrows) and/or rosettes (Figure 6A top,
arrowheads). Quantification of the number of cells displaying such
structures revealed a 40 to 50% decrease in FAKI936/I998 and
FAK-/- cells respectively as compared to FAK cells (Figure 6B). It
has been reported that Src localizes to FAs via binding to FAK at
Tyr397 [28]. Indeed, as observed by the reduction of Src-paxillin
co-localization (Figure 6A bottom panels) in FAK-/- or FAKI936/
I998 cells, mCherry-SrcY530F targeting to FAs appears inhibited,
but remains in other cell membrane (arrows) and cytoplasmic
regions. Thus, one of the effects of the FAKI936/I998 mutation may
be the displacement of Src from active sites. The invasive
properties of Src-transformed MEFs were then evaluated in
invasion assays in which the cells degrade and migrate through
Matrigel. Using this assay, invasion of both FAK-/-/SrcY530F and
Figure 5. Effect of FAKI936/I998 expression on adhesion and
migration. (A) For adhesion assay, cells were seeded in fibronectin-
coated wells and allowed to adhere for 1 h before quantification.
(P,0.0001, F = 28.96; 3 independent experiments done in sextupli-
cates). ***p,0.0001 versus FAK cells, {p,0.02 versus FAK-/- cells. (B) For
migration assays, confluent cell monolayers were wounded and cells
were allowed to migrate for 8 h. Images were taken at t = 0 and t = 8 h,
and the distance covered by migrated cells was evaluated. (P,0.0001,
F = 21.57; 3 independent experiments done in triplicates). ***p,0.0001
versus FAK cells, *p,0.02 versus FAK cells, {{p,0.005 versus FAK-/- cells.
doi:10.1371/journal.pone.0092059.g005
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FAKI936/I998/SrcY530F cells were significantly less than for wild-
type FAK/SrcY530F cells (Figure 7). These results show that the
invasive phenotype triggered by active SrcY530F expression is
inhibited in FAK-/- or FAKI936/I998 cells.
Gain of function of FAKI936/I998
In our functional tests, we observed a decrease in adhesion,
migration and invasion of FAKI936/I998-expressing cells often
superior to those observed in FAK-/- cells. This led us to suppose
that FAKI936/I998 may have additional functions by sequestrating
key signalling molecules outside FAs. As FAK has been proposed
Figure 6. Cortactin and paxillin distributions in FAK-/-, wild-type FAK and FAKI936/I998 cells co-transfected with active Src. (A)
Fluorescence images taken at the base of fixed cells expressing wild-type or mutant GFP-FAK and mCherry-SrcY530F and immunostained for cortactin
(upper panel) or paxillin (lower panel). Note the presence of cortactin clusters organized in rosette-like (arrowhead) or dot-like (arrow) structures
characteristic of Src transformation in FAK cells and the absence of such structures in FAKI936/I998/SrcY530F cells. Note also the membrane localization
of SrcY530F in FAKI936/I998 and FAK-/- cells (arrows). Scale bars, 5 mm. (B) Quantification of the percentage of cells having cortactin clusters at their base
in the different conditions above. Note the reduced amount of cells with cortactin clusters in FAK-/- and FAKI936/I998 expressing cells. (P = 0.0003,
F = 40.92; **p,0.003, ***p,0.002 versus FAK cells, 3 independent experiments with approximately 100 cells counted for each condition).
doi:10.1371/journal.pone.0092059.g006
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to mediate Src targeting to FAs [28], we began to investigate this
property by analysing the activation state of Src at FAs in our cells
lines. To do so, immunochemistry experiments were done using
antibodies directed against paxillin, to identify FAs and the
phosphorylated form of Src at Tyr-416, a hallmark of Src activation
states [29,30]. The intensity of paxillin fluorescence at FAs was
independent of FAKI936/I998 expression level (Figure S2). We found
that Src phosphorylation at FAs is reduced, but not supressed, in
non-transfected cells and in cells expressing FAKI936/I998 as
compared the FAK-expressing cells (Figure 8A). To quantify
the degree of Src activation at FAs, FAs were first segmented and
then subjected to colocalisation analysis using Pearson’s coeffi-
cient, which calculates the degree of overlap between paired
images (Figure 8B). It appears that Src activation was lower in
FAKI936/I998 and FAK-/- cells compared to FAK-expressing cells.
Moreover, the increased severity of Src inactivation in cells
expressing FAKI936/I998 compared to FAK-/- cells (Figure 8B),
suggests that FAKI936/I998 may sequester Src outside FAs. To
verify our hypothesis, co-immunoprecipitation experiments were
performed. The results show that FAKI936/I998 was able to
precipitate Src in a manner comparable to FAK WT although
Src activity state was reduced in the complex (Figure 8C).
Therefore, this suggests that FAK-Src complex pre-exists in the
cytosol thus further validating the sequestration property of the
FAK mutant. Our Western-blot experiments revealed also that
p130Cas was slightly reduced in FAKI936/I998 cells compared to
FAK-/- cells (Figure 2). Because FAK has been shown to mediate
p130Cas phosphorylation either directly or via formation of a
complex with Src at FAs, we assayed whether lack of FAK
localisation at FAs alter p130Cas phosphorylation at these sites.
Immunohistochemistry experiments revealed that p130Cas
expression at FAs was similar in both FAK-/-, FAK and
FAKI936/I998 cells (Figure 9A) while p130Cas phosphorylation
was reduced in FAKI936/I998 cells as compared to FAK cells but
also to FAK-/- cells (Figure 9B). Taken together, these data
demonstrate that FAKI936/I998 displays gain of function effects,
thus leading to an enhanced reduction of adhesion and migration
properties.
Discussion
FAK is involved in many aspects of the cancer process and
clinical studies have revealed a clear link between FAK expression
and/or phosphorylation and cancer aggressiveness. Therefore, the
current development of strategies aimed at inhibiting FAK is of
potential therapeutic interest. While classical inhibitors of the
kinase domain of FAK are effective in animal models, a promising
alternative may be to inhibit the scaffolding function of FAK,
thereby preventing interaction of FAK with its various binding
partners. As many functions of FAK are related to the efficient
localization of FAK at FAs, we used site directed mutagenesis to
disrupt the two paxillin binding sites in the FAT domain. We
found that mutations at Ile936, localised in the hydrophobic patch
2 (HP2) and Ile998, localised in the hydrophobic patch 1 (HP1) of
the FAT domain, completely abolished both FAK-paxillin
interaction and targeting of FAK to FAs in fibroblasts. These
mutations have been previously used in-vitro to test the interaction
between the N-terminal domain of paxillin (1–313) and the C-
terminal domain of FAK (904-1052) [13]. Here, we characterized
the effect of these mutations in living cells having full length
paxillin and FAK and report that FA dynamics were altered, cell
adhesion disrupted and migration and invasion processes de-
creased.
Previous studies have already shown that specific mutations of
the FAT domain altered FAK-paxillin interactions. Inhibition of
paxillin binding to HP1 could be done with the triple mutation
E949A/K956A/R963A into the a-helices 2/3 [31]. In this study,
when both paxillin binding sites are deleted by the additional
mutation of I937A on HP2, FAK localized to adhesions in only
10% of cells, contrarily to the complete delocalization of FAK
observed in our study. The authors suggested that, because both
paxillin binding sites were mutated, the residual fraction of FAK at
FAs was due to FAK targeting by talin in agreement with early
deletion studies identifying a 48 amino-acid sequence in the Ct
region of FAK (952–1012) necessary for binding to talin [32]. As
this sequence includes I998, mutation at this site may potentially
alter FAK-talin interaction. Indeed, by combining the triple
mutation E949A/K956A/R963A with both I937A/I998A muta-
tions, these authors observed a complete loss of FAK at FAs.
Nevertheless, as seen in Figure S1A, talin is correctly localized at
FAs in FAK cells but also in FAKI936E/I998E and FAK-/- cells.
Moreover, as talin interacts with both FAK and FAKI936/I998
(Figure S1B), I998 mutation did not alter the ability of FAK to
form a complex with talin. Taken together, these results show that
talin may not be involved in FAK targeting to FAs as previously
thought. This is in agreement with a recent study mapping FAK-
talin interaction to a FAK 1011–1042 domain and demonstrating
that during nascent FAs formation, its indeed FAK that targets
talin to these sites and not the contrary [24].
Formerly, it has been shown that chicken embryo cells
expressing FAK with deletions into the FAT domain like dl853–
963 or dl965–1012 were defective for paxillin phosphorylation and
adhesion regulation of FAK [15,33]. Conversely, in these cells
over-expression of FAT delayed cell spreading and reduced FAK
tyrosine phosphorylation [34] while in astrocytoma, FAT over-
expression reduced FAK phosphorylation and invasion in a
Figure 7. Invasion of FAK-/-, wild-type FAK and FAKI936/I998 cells
co-transfected with active Src. Transfected cells were seeded in
Matrigel-coated Boyden chambers and allowed to invade for 24 h.
Invading cell nuclei were stained with crystal violet and ODs were
measured at 595 nm. Bright field images were taken at 46
magnification. Scale bar, 100 mm. (P = 0.0030, F = 7.795; *p,0.03,
**p,0.002 versus wild-type FAK cells from 3 independent experiments
done in triplicates).
doi:10.1371/journal.pone.0092059.g007
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Figure 8. P-Src distribution and interaction in FAK-/-, wild-type FAK and FAKI936/I998 cells. (A) Confocal images of fixed FAK-/-cells
expressing or not (NT, non-transfected cells) wild-type or mutant FAK-GFP (left panel) and immunostained for paxillin (middle panel) or Src
phopsphorylated at tyr 416 (right panel). Note the high level of P-Src at FAs (arrows), identified by paxillin staining, in GFP-FAK cells (upper panel) and
the lack of P-Src staining at FAs in FAKI936/I998-GFP cells (lower panel). Note also the low level of P-Src at FAs in non-transfected (NT) FAK-/- cells
(arrowheads). Scale bar, 10 mm, insert scale bar, 5 mm. (B) Analysis of the localisation pattern of P-Src and paxillin in the different conditions above.
FAs were first segmented and then subjected to co-localisation analysis. Co-localised pixels between paxillin staining (left) and P-Src staining (middle)
appear in white on the colocalised image (right) Scale bar, 10 mm.Quantification using Pearson’s coefficient (which describes the extent of overlap
between image pairs) reveals a significant reduction of correlation in paxillin and P-Tyr416-Src images for both FAKI936/I998 and FAK-/- cells compared
to FAK cells (P,0.0001, F = 39.25; ***p,0.0001, n = 3 independent experiments with 15 to 27 cells analyzed) and for FAKI936/I998 cells compared to
FAK-/- cells ({{p,0.005, n = 3 independent experiments with 21 to 27 cells analyzed). (C) Representative blots showing wild-type FAK and FAKI936/I998
immunoprecipitated using anti-FAK Ab and blotted for FAK, Src and phospho-Src. The expression level of proteins in the corresponding cell lysate is
shown.
doi:10.1371/journal.pone.0092059.g008
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Boyden chamber Matrigel assay [35] reminding the phenotype
observed in our study. The downstream effect of FAK inhibition
could be due either to reduced phosphorylation of FAK substrates
like paxillin and p130Cas and/or to reduced binding of FAK
partners. At least 6 phosphorylatable tyrosines that might
potentially bind SH2-containing proteins are present in FAK.
Inhibition of FAK targeting to FAs led to reduced phosphorylation
of FAK at Tyr397, Tyr576 and Tyr925. In living cells it has been
shown, using forced dimerization, that FAK autophosphorylation
is essentially intermolecular and requires the presence of the C-
terminal targeting region of FAK, presumably because of the local
enrichment of FAK at FAs [36]. Therefore, consistently, we
observed that lack of FAK localization to adhesion sites
dramatically reduces Tyr397 phosphorylation. Src binding to
FAK promotes further phosphorylation of FAK at additional
tyrosines and full catalytic activation of the kinase [37–39]. Tyr576,
which lies within the kinase domain of FAK, is a marker of FAK
kinase activity [37]. Thus, the reduced degree of phosphorylation
of this site observed in our study could reflect the reduced binding
of Src to FAK. This is also consistent with the reduced
phosphorylation observed at Tyr925, since phosphorylation on
this residue is significantly reduced in cells expressing a kinase-
defective mutant of Src [40].
Mutation of FAK at Ile936 and Ile998 led to an overall reduction
in the number of small adhesions, especially those with size under
1 mm2, which could be due to the reduced phosphorylation of
FAK at Tyr925 as phosphorylation at this site has been shown to be
important for the formation of nascent adhesions [41]. This
phenotype was also observed in FAK-/- cells or when cells were
transfected with FRNK, the dominant negative form of FAK [42].
Other studies have implicated the phosphorylation state of paxillin
in the control of adhesion turn-over. Indeed, using paxillin-/- and
paxillin-/- cells expressing either paxillinY31F, paxillinY118F or
paxillinY31F/Y118F, it was demonstrated that paxillin phosphoryla-
tion is essential for adhesion turn-over [26]. In addition, in vitro
studies have shown that FAK phosphorylates paxillin at Tyr 31
and 118 [33,43,44]. As FAKI936/I998 is unable to bind paxillin, its
phosphorylation state is consequently reduced and therefore, our
study characterizes a new way to alter FA dynamics via reduction
of both FAK and paxillin phosphorylation states. Moreover,
binding of p130Cas to FAK is linked to enhanced tyrosine
phosphorylation of p130Cas, resulting in the activation of Rac,
lamellipodia formation and promotion of cell motility as we and
others have previously shown [45–47]. Thus, our results suggest
that displacing FAK from FAs, which led to reduced paxillin and
p130Cas phosphorylation, alters migration via both reduction of
FA turnover and lamellipodia formation. It is interesting to note
Figure 9. p130Cas distribution in FAK-/-, wild-type FAK and FAKI936/I998 cells. (A) Confocal images of fixed FAK-/-cells expressing or not (NT,
non-transfected cells) wild-type or mutant FAK-GFP (left panel) and immunostained for p130Cas (right panel). Note the localization of p130Cas at FAs
in both FAK-/-, FAKI936/I998 and FAK cells. Scale bar, 20 mm. (B) Confocal images of fixed FAK-/-cells expressing or not (NT, non-transfected cells) wild-
type or mutant FAK-GFP (left panel) and immunostained for P-p130Cas (right panel). Note the high level of P-p130Cas at FAs in GFP-FAK cells (upper
panel) and the lack of P-p130Cas staining at FAs in FAKI936/I998-GFP cells (lower panel). Scale bar, 20 mm. Quantification of the mean fluorescence
intensity at FAs shows a significant reduction of P-p130Cas staining for both FAKI936/I998 compared to FAK and FAK-/- cells and for FAK-/- cells
compared to FAK cells (P = 0.0005, F = 9.434; ***p,0.0005, *p,0.05 and {p,0.05 respectively, n = 3 independent experiments with 12 to 15 cells
analyzed and more than 300 FAs analyzed for each condition).
doi:10.1371/journal.pone.0092059.g009
FAK-Paxillin Interactions in Invasion Processes
PLOS ONE | www.plosone.org 11 March 2014 | Volume 9 | Issue 3 | e92059
that Ile936 and Ile998 mutations led to greater decreases in
adhesion and migration compared to FAK-/- cells, indicating that
FAKI936/I998 mutation triggers effects that go beyond FAK
removal. Indeed, the global state of p130Cas phosphorylation, as
assessed by western-blotting, was slightly reduced in FAKI936/I998
cells compared to FAK-/- cells, although this reduction is clearly
evident at FAs (Figure 9B). Nevertheless, this reduction did not
correlate with a reduction of p130Cas expression level at FAs
suggesting that FAK is not a key determinant for p130Cas
targeting to FAs. This is in accordance with previous studies
showing that p130Cas localizes to FAs via both FAK dependent
and independent manner [48]. Indeed, in FAK-/- cells, p130Cas
localizes to FA via a mechanism that may implicate the ‘‘Cas-
family C-terminal homology’’ (CCH) domain which can adopt a
tertiary structure similar to the FAT domain of FAK, and/or bind
to the LIM protein Ajuba for targeting to nascent adhesion [49].
The gain of function effect of FAKI936/I998 was confirmed by
analysing the cellular location of Src, another key binding partner
of FAK. We show that Src activation state at FAs is decreased in
FAKI936/I998-expressing cells as compared to FAK-/- cells. This
suggests that the mutated form of FAK is able to sequester key
binding partners outside FAs, necessary for FA disassembly. In
support of this finding we show that FAKI936/I998 bound to Src
and therefore, because FAKI936/I998 is not localized at FA, this
result suggests that FAKI936/I998 form a complex with Src within
the cytosol.
When fibroblasts were transfected with the constitutively active
form of Src, we observed a transformed phenotype characterized
by the presence of invadopodia, as previously described [28]. We
found that inhibiting FAK localization to FAs reduces the number
of cells displaying invadopodia close to the value observed for
FAK-/- cells (Figure 6B). This leads to a less invasive phenotype as
observed by the reduced invasion through Matrigel (Figure 7), in
agreement with prior studies demonstrating that FAK is required
for cell invasion through Matrigel in v-Src-transformed FAK-/-
fibroblasts [47]. In this latter study, cell invasion was linked to the
formation of a complex containing FAK, Src and p130Cas that is
necessary for increased MMP activity. More recently, in several
cancer cell lines, MT1-MMP-induced matrix degradation at FAs
has been described for which the association of the FAK–p130Cas
complex at these sites is required [50]. Therefore, alteration of
FAK targeting to FAs, which affects p130Cas phosphorylation,
could be responsible for the reduced invasion observed in
FAKI936/I998 cells (Figure 7). We also show that Src localization
to paxillin-containing structures is enhanced by FAK targeting at
FAs (Figure 6A). Using time-lapse video of GFP-tagged vinculin, it
has been found that Src-transformed NIH3T3 cells assemble
podosomes at FAs, therefore supporting the notion that podo-
somes might be initiated at these sites [51].
In summary, we have shown that inhibiting FAK-paxillin
interactions led to altered FAK localization at FAs which in turn
results in reduced phosphorylation of FA proteins and impaired
adhesion, migration and invasion processes. Our study also
demonstrates that the effects of inhibiting FAK targeting to FAs
appears to be greater that complete knockout of FAK. This
supports that targeting the FAK ‘‘interactor’’ instead of the FAK
kinase domain may well be a valuable strategy for the search of
novel FAK inhibitors to treat metastatic cancer.
Supporting Information
Figure S1 Talin distribution and interaction in FAK-/-,
wild-type FAK and FAKI936/I998 cells. (A) Confocal images
from fixed cells expressing wild-type or mutant FAK and
immunostained for talin (red). Note the presence of talin at FAs
in both FAK-/-, FAKI936/I998 and FAK cells. Scale bar, 20 mm. (B)
Representative blots showing wild-type FAK and FAKI936/I998
immunoprecipitated using anti-talin Ab and blotted for FAK and
talin. The expression level of proteins in the corresponding cell
lysate is shown.
(TIF)
Figure S2 Paxillin distribution in FAKI936/I998 cells.
Confocal images from fixed cells expressing FAKI936/I998 and
immunostained for paxillin (red). Note the equal expression level
of paxillin at FAs in both FAKI936/I998 and FAK-/-, cells. Scale
bar, 20 mm.
(TIF)
Movie S1 Fluorescence image sequence of a FAK-/- fibroblast
expressing CFP-paxillin. TIRF images are taken at 1 min interval
for 1 hour.
(AVI)
Movie S2 Fluorescence image sequence of a FAK-/- fibroblast
expressing wild-type FAK and CFP-paxillin. TIRF images are
taken at 1 min interval for 1 hour.
(AVI)
Movie S3 Fluorescence image sequence of a FAK-/- fibroblast
expressing FAKI936/I998 and CFP-paxillin. TIRF images are taken
at 1 min interval for 1 hour.
(AVI)
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